IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Barbara A. Gilchrest, et al.

Docket No:

06225.0004.PCUS00

App. No.:

10/553,001

Art Unit:

1635

To be assigned

Conf. No.: Filing Date: 9118 July 24, 2006 Examiner: Title:

MODULATION OF TELOMERE-

INITIATED CELL SIGNALING

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, and §§ 1.97 - 1.987 as supplemented by MPEP § 609, Applicants call to the attention of the Examiner the references listed on the attached Forms PTO/SB/08A and PTO/SB08B. It is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Forms PTO/SB/08A and PTO/SB/08B be considered by the Examiner and made of record. A list of all enclosed documents is provided in a Form PTO-1449, transmitted herewith. Presentation of documents listed on enclosed Form PTO-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 C.F.R. § 1.131 or otherwise.

This information disclosure statement is being filed within three months of the filing date of the above-cited patent application or prior to the mailing of a first Office action on the merits, in accordance with 37 CFR § 1.97(b). Accordingly, Applicants respectfully request that the statement be considered by the Office in the course of prosecution of the application.

Docket No. 06225,0004.PCUS00

U.S. Application No.: 10/553,001

This Information Disclosure Statement does not include copies of cited U.S. patents and U.S. patent publications pursuant to 37 C.F.R. 1.98(a)(2).

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR §1.97(g)), an admission that the information cited is or is considered to be material to patentability, or that no other material information exists.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to this document, the Commissioner is hereby authorized to deduct the fees from Howrey LLP Deposit Account 08-3038.

Respectfully submitted, HOWREY LLP

Dated: December 28, 2006

By:

David W. Clough, Ph.D. Registration No.: 36,107 Customer No.: 22930

Telephone No.: (312) 595-1408

Enclosures:

Form PTO-SB-08A and SB-08B

HOWREY LLP

ATTN: Docketing Department 2941 Fairview Park Drive, Suite 200 Falls Church, VA 22042-9922 Telephone No.: (703) 663-3600

Facsimile No.: (703) 336-6950

PTO/SB/08a (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE nation unless it contains a valid OMR control number

	Under the Paperwork Reduction Apt of 1995 no Persons are required to		Complete if Known		
St	ubstitute for form 1449A/PTO		Application Number	10/553,001	
- 1	NFORMATION DISCI	OSURE	Filing Date	July 24, 2006	
•	STATEMENT BY APP	LICANT	First Named Inventor	Barbara A. Gilchrest	
•	(Use as many sheets as necessary)		Art Unit	1635	
			Examiner Name	To be assigned	
Sheet	T	of 2	Attorney Docket Number	06225.0004.PCUS00	

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	A1	Number-Kind Code ^{2 (f known)} 5,958,680	09/28/1999	Villeponteau, et al.		
	-	0,000,000				
	+					
	+					
	+					
	+					
	+					
	+					
	+					

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Do	Patentee or Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁴
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)					
	-						\vdash
					<u></u>		\vdash
	-						
				L			<u> </u>
Examiner Signature					Date Considered		

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional). "See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST3," For Japanese patent documents, the indication of the year of the reign or the Emperor must precede the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

entains a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			PTO	Complete if Known		
			DISCLOSURE	Application Number	10/553,001	
				Filing Date	July 24, 2006	
				First Named Inventor	Barbara A. Gilchrest	
			eets as necessary)	Group Art Unit	1635	
				Examiner Name	Not yet assigned	
Sheet	1	of	1	Attorney Docket Number	06225.0004.PCUS00	

NON PATENT LITERATURE DOCUMENTS				
Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²		
C1	Anselmet, A., et al., "Non-Antisense Cellular Responses to Oligonucleotides," FEBS Letters, Vol. 510, pp. 175-180 (2002)			
C2	in Vitro by Antisense Oligonucleotides," Biochemical and Biophysical Research Communications, Vol. 248, pp. 368-371 (1998)			
C3	Zhihui, L., et al., "Inhibitory Effect of a Liposome-Mediated Antisense Oligodeoxynucleotide on Telomerase Activity in a Human Gastric Cancer Cell Line," Chinese Journal Of Digestive Diseases, Vol. 2, pp. 65-68 (2001)			
	No. 1 C1 C2	Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published C1 Anselmet, A., et al., "Non-Antisense Cellular Responses to Oligonucleotides," FEBS Letters, Vol. 510, pp. 175-180 (2002) C2 Glukhov, A., et al., "Inhibition of Telomerase Activity of Melanoma Cells in Vitro by Antisense Oligonucleotides," Biochemical and Biophysical Research Communications, Vol. 248, pp. 368-371 (1998) C3 Zhihui, L., et al., "Inhibitory Effect of a Liposome-Mediated Antisense Oligodeoxynucleotide on Telomerase Activity in a Human Gastric Cancer		

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

CALCHINES. Initial it resence considered, mention to consolute the considered include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional)

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering. preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Transition Officer, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.